-

Thermo Fisher Scientific Elects New Director to Board

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Jenny Johnson, president and chief executive officer of Franklin Resources, Inc. (NYSE:BEN), has been elected to its board of directors. The appointment brings the total number of Thermo Fisher board members to 12.

In a career at Franklin Templeton spanning 35 years, Johnson has been a key driver in the company's transformation to what is now one of the largest global asset managers with over $1.4 trillion in assets under management. Johnson has held leadership roles in all major divisions of the business, including investment management, distribution, technology, operations and wealth management, before becoming CEO in February 2020. Johnson is also a board member of Franklin Resources, Inc.

"Jenny is an accomplished business leader with operational, technological and strategic experience and vision," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "We are excited to welcome Jenny to the board where her insights will bring significant value to our board as we continue to deliver on our Mission of enabling our customers to make the world healthier, cleaner and safer.”

In 2022, Forbes named Johnson to its World's 100 Most Powerful Women and 50 Over 50 lists. She has also been named to Barron's list of the 100 Most Influential Women in U.S. Finance for four consecutive years, most recently in 2023. Johnson earned a Bachelor of Arts degree in Economics from the University of California at Davis.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com

Investor Contact:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com

Investor Contact:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar**, new color-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species — including Candida auris, a growing global antimicrobial resistance (AMR) threat1. Invasive fungal infections are an increasing challenge for healthcare systems w...

Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection. For transplant recipients, finding the right tacrolimus dose as early as possible can be life-changing. If the dose is too low, the body may...

Thermo Fisher Scientific Increases Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40...
Back to Newsroom